Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33382749

about

Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma Antiangiogenic mechanisms and factors in breast cancer treatment EGFR Signaling in Liver Diseases Systemic therapy of hepatocellular carcinoma: current status and future perspectives Targeted therapy for hepatocellular carcinoma: novel agents on the horizon Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma Combination treatment including targeted therapy for advanced hepatocellular carcinoma Hepatocellular carcinoma: Where there is unmet need Molecular classification and novel targets in hepatocellular carcinoma: recent advancements Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.Liver cancer: Targeted future options V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.Novel therapeutic strategies for targeting liver cancer stem cells.Targeting metastatic upper gastrointestinal adenocarcinomas Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.Targeted therapy in hepatocellular carcinoma Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review HCC and angiogenesis: possible targets and future directions Mixed response and time-to-event endpoints for multistage single-arm phase II design Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.

P2860

Q24316017-302BE6A2-C7B1-4EBD-BE8D-488286908CC8 Q26751226-281E79DD-64C3-4BB6-B210-E631D75F2CC9 Q26771265-69484DF3-04B6-4D60-B83D-68558059834B Q26865844-CEAFBFC2-1C52-41A2-B1BB-1E545BABACD0 Q27002288-235F947E-3E4D-4938-B56C-F3EBC2626BF9 Q28075305-FD136B1B-66BF-4D5F-BFBC-211BFB941C1F Q28077738-175C7CF5-97F8-4403-B64B-CD4F43E6A5A0 Q28084046-16706400-69A2-44D8-93D5-5F5325B7B573 Q28383646-E4C36285-9372-480A-87A2-1654D410A1FE Q30234736-A2E41FE6-DFB5-4DE0-8F88-E0A7E75FEA4C Q33419633-71C0E645-670A-47B0-97F2-3754C67E50FA Q33660974-149D9899-8819-48B7-8CF3-4EC0D12C76B6 Q33742856-7D6A590F-649B-4352-93D9-BAC54839BE95 Q33747394-F4B9F67B-0E07-4C5D-871B-3DE8738EFA42 Q33802709-8D7471EF-D472-4367-A7D0-505908C1E3B5 Q34048813-6C20C701-DF1A-4D3E-B1F6-8A4B4E79FBF9 Q34131801-44735B79-C51D-4E52-A5DE-907E7C631E4F Q34168811-E583FA76-74E1-481F-A482-BFFA768AC9FA Q34197835-1E2C17FB-DC3A-4762-98A7-7B929CD8AB5C Q34409128-7A554D5A-C0A4-4826-A29C-54C5F51B5C1A Q34504649-2FABB4B2-DBE1-4EF5-B1B4-0C93E5135E5F Q34531474-9649070C-F9AC-4AF7-AE6D-8BD7EFA1F2B8 Q34548464-DE439D57-4BF1-42A5-A1CF-9F9EEE8F2CA4 Q34695180-90441877-D834-4320-840D-6334EE09AB6D Q34733478-4BA86575-B873-4BF8-AB74-397D38F1E434 Q34940971-B547882C-7C03-47F1-9497-99C168765087 Q35000785-56A09EC5-B32E-453E-A433-B718D15CD1F0 Q35078518-8D570326-E690-440C-9D72-725E99AA220D Q35207561-AA4B94AA-B986-45C1-8E66-4CAF2C3DF723 Q35230282-B2D184E4-3D62-44A2-8548-011FA4C6E1E1 Q35501246-A26C3462-6F42-4768-9920-608392DC4333 Q35541482-384E102C-DCFF-48E2-BFBC-C8D1A59BFB24 Q35584543-3DC3A6BC-190F-4D4A-BE04-1DBD2FC98E03 Q35698574-261E38A3-0BE7-4153-AB40-88ABB698D7E5 Q35700578-BCE2E071-95C9-4E24-8441-2E94C573BAA9 Q35759606-74E7C5F1-D697-41B5-89FD-ABB88D9AB268 Q35856029-43EE7E1B-B24E-46E2-97F1-7E1DE5E6BB23 Q35884134-BCD6A04B-C536-4F8C-A1D0-0446B15A6782 Q35913461-764050DF-4950-4198-A7EE-46754EA1BE9B Q36182824-5F80BC7D-5346-48FC-8BD8-ACD9F6C80A4D

P2860

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33382749

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II trial of the combinat ...... nced hepatocellular carcinoma.

@ast

Phase II trial of the combinat ...... nced hepatocellular carcinoma.

@en

type

label

Phase II trial of the combinat ...... nced hepatocellular carcinoma.

@ast

Phase II trial of the combinat ...... nced hepatocellular carcinoma.

@en

prefLabel

Phase II trial of the combinat ...... nced hepatocellular carcinoma.

@ast

Phase II trial of the combinat ...... nced hepatocellular carcinoma.

@en

P1433

Q33382749-11F88344-98F0-41E5-A67F-952A13D18E3A

P1476

Q33382749-74FF7433-0F23-454A-A7B6-7D3E870C7457

P2093

Q33382749-2760871B-E165-4BA0-BFD0-DF46AEDF0F34

Q33382749-3727EAC4-23F8-49E9-A57F-EB14DF24806C

Q33382749-685311E5-723E-4F5E-9562-8E5924B7916F

Q33382749-76D483FD-E23E-4E53-BBBF-7D48CB3E9D0D

Q33382749-9445ACF7-2BD7-4D87-AB5A-336A1B101E17

Q33382749-A483B48C-9904-41B5-B505-ACF3235CE836

Q33382749-CA3F357A-5F24-4C9B-B25D-53D2A2A919A4

Q33382749-E0019783-336A-466D-B9D4-77F1CD17F229

P304

Q33382749-A3A9FEBA-1472-4E71-B966-6DAE8D75176F

P31

Q33382749-F133DF64-28F3-41EC-95FD-4EAB50CD16A0

P356

Q33382749-BB65CF9B-B69D-4538-A851-0C7CC14E7B5B

P407

Q33382749-71C1FC63-D34E-48A8-869E-BF1BBF32E8AB

P433

Q33382749-DB9421C4-2D1C-49E0-A398-15C7392B3ED8

P478

Q33382749-A5341A3C-0D2A-46D9-912F-577651CC1BFE

P50

Q33382749-2B91B553-BAF7-482F-97E0-562C329541B1

Q33382749-CF1F67A4-181D-4415-9492-51CC850B2DF6

P577

Q33382749-76F61FCD-B4A7-44E2-8E89-F25D0D77CAB4

P698

Q33382749-BB77DADD-C743-4DF7-AC7E-1BE9562EB72B

P921

Q33382749-365F5E5D-FC91-4DCF-98E4-783B23B28DC1

Q33382749-5BB7C86A-6937-45C9-8DBC-3AE3825B95C6

Q33382749-6167F052-A874-44EB-BDA7-F3BC960537EB

P356

JCO.2008.18.3301

P1433

Journal of Clinical Oncology

P1476

Phase II trial of the combinat ...... anced hepatocellular carcinoma

@en

P2093

Ahmed Kaseb

http://www.w3.org/2001/XMLSchema#string

E Lin

http://www.w3.org/2001/XMLSchema#string

James Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Morris

http://www.w3.org/2001/XMLSchema#string

Katrina Glover

http://www.w3.org/2001/XMLSchema#string

Marta Davila

http://www.w3.org/2001/XMLSchema#string

Melanie B Thomas

http://www.w3.org/2001/XMLSchema#string

Michiko Iwasaki

http://www.w3.org/2001/XMLSchema#string

P304

843-850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.3301

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19139433

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial